Voluntary Disclosure of GSK in Canada payments to HCPs and HCOs in 2019
Our commitment to transparency
GSK, like most other innovative pharmaceutical companies, engages with healthcare professionals (HCPs) who are considered experts in their field. We believe that it is appropriate to compensate healthcare professionals for their time and investment.
Globally, GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system. Transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines and improve clinical practice and care for patients.
We are pioneers
Unlike many other jurisdictions, there is no requirement in Canada for pharmaceutical companies to disclose payments made to HCPs or Healthcare Organizations (HCOs). However, since 2017, GSK has been among ten leading pharmaceutical companies in Canada that have voluntarily disclosed in aggregate payments to HCPs and payments to HCOs.
Starting this year, GSK alongside ViiV Healthcare, are voluntarily expanding the reporting to include payments to individual HCPs. Although disclosing at the individual HCP level is not consistent with the industry approach in Canada, it does align to both GSK’s global commitment and what is required of the pharmaceutical industry in many other countries, including the US, European countries, Australia and Japan.
Where an HCP requested payment to their corporation, those HCPs will be excluded from individual disclosure for this year only.
The important relationship between industry and HCPs
The relationship between healthcare companies and HCPs is an essential part of patient care, disease understanding, as well as the research and discovery of innovative medicines in Canada. By continuing to be transparent on these relationships, we are evolving with society’s expectations.
In Scope Activities
GSK engages with HCPs and HCOs to foster scientific exchange which benefit patients. These interactions are bound by local and international laws and regulated by Innovative Medicines Canada’s Code of Ethical Practices.
What are payments or transfers of value (TOV)?
They are payments or contributions made to HCPs or HCOs. Healthcare organizations (HCOs) are any private or public sector organization, institution or association that is comprised of HCPs and/or that provides healthcare services, and also includes a clinic or medical practice consisting of one or more HCPs.
What are the collaborations for?
- Grants to HCOs
- Training activities and scientific professional meetings
- R&D activities
- Provision of services such as consulting
What does individual disclosure mean?
For the reporting of 2019 payments, we are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services.